Mean (SD) change from baseline in WLQ and EQ-5D scores at week 52a
| Outcome | Placebo | Sirukumab 50 mg q4w | Sirukumab 100 mg q2w |
|---|---|---|---|
| WLQ | (n=227) | (n=223) | (n=221) |
| Production loss (total) score | −0.73 (5.03) | −3.06 (4.53)b | −2.94 (4.39)b |
| Domain scores | |||
| Mental-interpersonal | −1.39 (21.09) | −8.45 (19.23)b | −8.69 (19.37)b |
| Output | −2.47 (24.17) | −12.39 (23.03)b | −12.18 (22.38)b |
| Physical demands | −4.70 (23.29) | −12.91 (22.27)b | −8.70 (21.00)c |
| Time management | −5.75 (25.52) | −16.54 (24.41)b | −16.38 (23.79)b |
| EQ-5D | (n=556) | (n=557) | (n=557) |
| Indexd | 0.13 (0.34) | 0.20 (0.33)b | 0.20 (0.33)b |
| Health state VAS | 8.30 (26.14) | 16.80 (28.60)b | 17.14 (28.33)b |
an values are based on initial treatment assignment and varied slightly for WLQ domain scores. bP<0.001. cP=0.047. dBased on UK TTO.